Integrating epigenetic and immune biomarkers to enable dynamic precision therapy in triple-negative breast cancer

Expert Review of Molecular Diagnostics 2026 Open access

Read full text
Authors: Jabed Iqbal, S. Chua
DOI: 10.1080/14737159.2026.2646564
Cited by: 1
References: 15

Abstract

1. Triple-negative breast cancer (TNBC) remains one of the most aggressive breast cancer subtypes, with 5-year survival of

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Epigenetics and DNA Methylation Immune cells in cancer

Publication details

Journal / source
Expert Review of Molecular Diagnostics
Publisher
Informa UK Limited
Volume
26
Issue
3
Pages
191–194
Publication date
4 March 2026
Language
EN